Using Pincer platform, Mediomics will develop antigen-specific assays for antibody titer, affinity, glycosylation and aggregation and is also expected to culminate with beta-testing by Gallus Biopharmaceuticals.
The company will collaborate with industry partners, Washington University and Gallus Biopharmaceuticals to develop applications for its Pincer platform.
Mediomics president Yie-Hwa Chang said the grant will help to move the cheaper, faster screening technology into mainstream applications.
"We expect the availability of the molecular PINCER®-based automated in-process analyzer will displace cumbersome benchtop instruments and gain acceptance for use in biologics production and food pathogen detection," Chang added.